Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 15INDUSTRY 6NIH 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 410Lymphoma 304Carcinoma, Non-Small-Cell Lung 262Melanoma 255Precursor Cell Lymphoblastic Leukemia-Lymphoma 251Prostatic Neoplasms 246Leukemia, Lymphocytic, Chronic, B-Cell 242Leukemia, Myeloid, Acute 222Lung Neoplasms 215Neoplasms 209Colonic Neoplasms 209Lymphoma, Non-Hodgkin 207Lymphoma, Large B-Cell, Diffuse 204Leukemia 200Multiple Myeloma 197Lymphoma, Follicular 197Colorectal Neoplasms 190Rectal Neoplasms 188Ovarian Neoplasms 184Burkitt Lymphoma 179Brain Neoplasms 171Neoplasm Metastasis 166Lymphoma, Mantle-Cell 163Carcinoma, Renal Cell 163Glioblastoma 161Sarcoma 156Pancreatic Neoplasms 146Lymphoma, B-Cell, Marginal Zone 143Unspecified Adult Solid Tumor, Protocol Specific 138Gliosarcoma 133

Interventions

resiniferatoxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Interventional × Pain, Intractable × Clear all
NCT00804154 2026-05-01

Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
45 enrolled

Cancer Pain, Pain, Intractable

NCT02522611 2026-04-13

Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain

National Institutes of Health Clinical Center (CC)

Phase 1/2 Not yet recruiting
30 enrolled

Cancer Pain, Pain, Intractable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡